{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T23:26:59Z","timestamp":1791415619208,"version":"4.3.3"},"reference-count":34,"publisher":"SAGE Publications","issue":"8","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Ocular Pharmacology and Therapeutics"],"published-print":{"date-parts":[[2024,10,1]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>Activation of the classical complement pathway is thought to contribute to the development and progression of glaucoma. The role of alternative complement or amplification pathways in glaucoma is not well understood. We evaluated complement factor B (FB) expression in postmortem human ocular tissues with or without glaucoma and the effect of FB inhibition and deletion in a mouse ocular hypertensive model of glaucoma induced by photopolymerized hyaluronic acid glycidyl methacrylate (HAGM).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      Human\n                      <jats:italic toggle=\"yes\">CFB<\/jats:italic>\n                      mRNA in human eyes was assessed by RNAscope and TaqMan. HAGM model was performed on C57BL6\/J mice. The effect of FB in HAGM model was evaluated with an oral FB inhibitor and\n                      <jats:italic toggle=\"yes\">Cfb<\/jats:italic>\n                      <jats:sup>\u2212\/\u2212<\/jats:sup>\n                      mice. Complement mRNA and proteins in mouse eyes were assessed by TaqMan and western blot, respectively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      <jats:italic toggle=\"yes\">CFB<\/jats:italic>\n                      mRNA in human glaucomatous macular neural retina and optic nerve head was upregulated.\n                      <jats:italic toggle=\"yes\">Cfb<\/jats:italic>\n                      mRNA is also upregulated in the HAGM model. Oral FB inhibitor, ED-79-GX17, dosed daily at 200 mg\/kg for 3 days after intraocular pressure (IOP) induction in wild-type mice showed complement inhibition in ocular tissues and significantly inhibited systemic complement levels. Daily dosing of ED-79-GX17 for 30 days or\n                      <jats:italic toggle=\"yes\">Cfb<\/jats:italic>\n                      deletion was also unable to prevent retinal ganglion cell or axon loss 30 days after IOP induction in mice.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>\n                      The alternative complement component FB may not substantially contribute to RGC loss in the HAGM mouse glaucoma model despite upregulation of\n                      <jats:italic toggle=\"yes\">Cfb<\/jats:italic>\n                      expression and activation of the alternative pathway. The relevance of these findings to human glaucoma remains to be determined.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/jop.2024.0046","type":"journal-article","created":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T12:38:23Z","timestamp":1720442303000},"page":"524-535","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":4,"title":["Complement Factor B Inhibition or Deletion Is Not Sufficient to Prevent Neurodegeneration in a Murine Model of Glaucoma"],"prefix":"10.1177","volume":"40","author":[{"given":"Katie","family":"Dolan","sequence":"first","affiliation":[{"name":"Ophthalmology, Novartis BioMedical Research (NBR), Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sha-Mei","family":"Liao","sequence":"additional","affiliation":[{"name":"Ophthalmology, Novartis BioMedical Research (NBR), Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maura","family":"Crowley","sequence":"additional","affiliation":[{"name":"Ophthalmology, Novartis BioMedical Research (NBR), Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanxi","family":"Xiang","sequence":"additional","affiliation":[{"name":"Ophthalmology, Novartis BioMedical Research (NBR), Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher M.","family":"Adams","sequence":"additional","affiliation":[{"name":"Global Discovery Chemistry, Novartis Institutes for Biomedical Research NBR, Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Brown","sequence":"additional","affiliation":[{"name":"Discovery\/Bioanalytics, Translational Medicine, Novartis Institutes for Biomedical Research NBR, Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nhi","family":"Vo","sequence":"additional","affiliation":[{"name":"Ophthalmology, Novartis BioMedical Research (NBR), Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Chen","sequence":"additional","affiliation":[{"name":"Ophthalmology, Novartis BioMedical Research (NBR), Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Delgado","sequence":"additional","affiliation":[{"name":"Ophthalmology, Novartis BioMedical Research (NBR), Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Buchanan","sequence":"additional","affiliation":[{"name":"Ophthalmology, Novartis BioMedical Research (NBR), Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenying","family":"Guo","sequence":"additional","affiliation":[{"name":"Ophthalmology, Novartis BioMedical Research (NBR), Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ganesh","family":"Prasanna","sequence":"additional","affiliation":[{"name":"Ophthalmology, Novartis BioMedical Research (NBR), Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,10,15]]},"reference":[{"issue":"3","key":"e_1_3_6_2_2","first-page":"276","article-title":"The ocular hypertension treatment study: A randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma","volume":"128","author":"Kass MA","year":"2002","unstructured":"Kass MA, , Heuer DK, , Higginbotham EJ, et al. Ocular Hypertension Treatment Study Group. The ocular hypertension treatment study: A randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol, 2002; 128(3):276\u2013287. discussion 729-730.","journal-title":"Arch Ophthalmol"},{"key":"e_1_3_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(98)00223-2"},{"key":"e_1_3_6_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.120.10.1268"},{"key":"e_1_3_6_5_2","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a017269"},{"key":"e_1_3_6_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/IJG.0b013e31818c6ef6"},{"key":"e_1_3_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2010.09.006"},{"key":"e_1_3_6_8_2","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.624983"},{"key":"e_1_3_6_9_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI44646"},{"key":"e_1_3_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2017.02.014"},{"issue":"12","key":"e_1_3_6_11_2","first-page":"2884","article-title":"Isoforms of nitric oxide synthase in the optic nerves of rat eyes with chronic moderately elevated intraocular pressure","volume":"40","author":"Shareef S","year":"1999","unstructured":"Shareef S, , Sawada A, , Neufeld AH. Isoforms of nitric oxide synthase in the optic nerves of rat eyes with chronic moderately elevated intraocular pressure. Invest Ophthalmol Vis Sci, 1999; 40(12):2884\u20132891.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_3_6_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2007.10.036"},{"key":"e_1_3_6_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/glia.22389"},{"key":"e_1_3_6_14_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-neuro-061010-113810"},{"key":"e_1_3_6_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2014.07.016"},{"key":"e_1_3_6_16_2","doi-asserted-by":"publisher","DOI":"10.1186\/1742-2094-10-76"},{"key":"e_1_3_6_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2018.08.017"},{"key":"e_1_3_6_18_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI25208"},{"key":"e_1_3_6_19_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.05-0830"},{"key":"e_1_3_6_20_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.10-5289"},{"key":"e_1_3_6_21_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0058657"},{"key":"e_1_3_6_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2023.100290"},{"key":"e_1_3_6_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2014.06.032"},{"key":"e_1_3_6_24_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1820892116"},{"key":"e_1_3_6_25_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0196529"},{"key":"e_1_3_6_26_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.62.7.26"},{"key":"e_1_3_6_27_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.17-22605"},{"key":"e_1_3_6_28_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12859-021-04344-9"},{"key":"e_1_3_6_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2019.12.082"},{"key":"e_1_3_6_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2006.03.002"},{"key":"e_1_3_6_31_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1608769114"},{"key":"e_1_3_6_32_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-019-1576-3"},{"key":"e_1_3_6_33_2","article-title":"Targeting the alternative complement pathway as a neuroprotective therapy in glaucoma and optic nerve injury","volume":"63","author":"Hoppe CG","year":"2022","unstructured":"Hoppe CG, , Guo Y, , Shrestha M, et al. Targeting the alternative complement pathway as a neuroprotective therapy in glaucoma and optic nerve injury. Invest Ophthalmol Vis Sci, 2022; 63:1609\u2013A0432.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_3_6_34_2","first-page":"1574","article-title":"The alternative complement pathway triggers neuroinflammation, glial activation, and retinal ganglion cell death in a microbead induced mouse model of glaucoma","volume":"64","author":"Hoppe CG","year":"2023","unstructured":"Hoppe CG, , Refain N, , Krasniqi D, et al. The alternative complement pathway triggers neuroinflammation, glial activation, and retinal ganglion cell death in a microbead induced mouse model of glaucoma. Investigative Ophthalmol Vis Sci, 2023; 64:1574.","journal-title":"Investigative Ophthalmol Vis Sci"},{"key":"e_1_3_6_35_2","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddac187"}],"container-title":["Journal of Ocular Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/jop.2024.0046","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jop.2024.0046","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jop.2024.0046","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T14:46:26Z","timestamp":1777646786000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/jop.2024.0046"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,1]]},"references-count":34,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,10,1]]}},"alternative-id":["10.1089\/jop.2024.0046"],"URL":"https:\/\/doi.org\/10.1089\/jop.2024.0046","relation":{},"ISSN":["1080-7683","1557-7732"],"issn-type":[{"value":"1080-7683","type":"print"},{"value":"1557-7732","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,1]]}}}